STIM
NEURONETICS (STIM)
NASDAQ
$1.38-$0.18 (-11.47%)
Price as of Jun 03, 2026 6:58 PM EDT
  • $107.2M
    Market Cap
  • -59.59%
    1-Year Change
  • Medical Devices
    Industry

Key Performance

More
  • Earnings Score: N/A
  • Momentum Score: 55
  • True Yield: N/A
  • Financial Health Score: N/A
TradeSmith Loading

Latest Research & News

Deal Dispatch: Unilever Buys Grüns, Pershing Square Eyes Universal Music Group, Saks Global Reorganization Plan

Major M&A activity includes Unilever acquiring gummy supplements maker Grüns for $1.2 billion, Bill Ackman's Pershing Square offering $63 billion for Universal Music Group, and Capital One completing its $2.56 billion acquisition of Brex. Meanwhile, several companies face financial distress with Asend Elements and National Road Logistics filing for Chapter 11 bankruptcy, and Saks Global Enterprises restructuring debt from its Neiman Marcus acquisition.

04/10/2026, 2:27 PM • Benzinga

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Neuronetics announced granting inducement awards of restricted stock units (RSUs) to twelve new employees, with vesting schedules contingent on continued employment over three years.

10/31/2025, 4:30 PM • GlobeNewswire

Peers

Statistics

More
Day Range
$1.56
$1.69
$1.56
1-Year Range
$1.18
$4.66
$1.56
Latest Close$1.56
Change
-$0.11 (-7.05%)
Volume1,117,891
Market Cap$107.2M
Shares Outstanding69.6M
P/E (TTM)-2.82
Diluted EPS (TTM)-$0.55
Enterprise Value$220.2M

Information as of 06/02/2026

Company Profile

$107.2M
Market Cap
-$37.1M
Net Income
Sector: Healthcare
Industry: Medical Devices
3222 Phoenixville Pike, Malvern, PA, United States, 19355
877 600 7555

Neuronetics, Inc. engages in providing in office treatments for patients with neurohealth disorders in the United States and internationally. The company provides NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.

Key Executives

  • Daniel L. Reuvers
  • W. Andrew Macan
  • Steven E. Pfanstiel
  • Lisa Metzner-Rosas
  • Jeffrey S. Jones

Current Ownership Distribution

  • Institutions362.6M (75.72%)
  • Mutual Funds88.2M (18.42%)
  • Insiders28.1M (5.87%)
  • Other0 (0.00%)